Latest news

16 May 2018
Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease
24 Apr 2018
Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved
19 Apr 2018
Idorsia announces financial results for the first quarter 2018
19 Mar 2018
Idorsia issues invitation to 2018 Annual General Meeting of Shareholders
06 Feb 2018
Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development
20 Dec 2017
Idorsia forms research collaboration with Roche in the field of cancer immunotherapy
04 Dec 2017
Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)
24 Oct 2017
Idorsia announces financial results as of 30 September 2017
03 Aug 2017
Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company
28 Jul 2017
ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
16 Jun 2017
Idorsia - Reaching out for more